Overview

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Status:
NOT_YET_RECRUITING
Trial end date:
2028-09-13
Target enrollment:
Participant gender:
Summary
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.
Phase:
PHASE3
Details
Lead Sponsor:
Amgen